Expanded Access to CA102N in One Patient Who Completed at Least 12 Cycles of Combination Therapy of CA102N Plus Lonsurf in Clinical Study Number of HS-CA102N-101
Latest Information Update: 01 Mar 2023
At a glance
- Drugs CA 102 N (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Holy Stone Healthcare
Most Recent Events
- 23 Feb 2023 Status changed from recruiting to suspended.
- 15 Mar 2022 New trial record